Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5313
Abstract: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration‐resistant prostate cancer (mCRPC) can facilitate shared‐decision making for optimal management. This study sought to elicit patient preferences for mCRPC treatments… read more here.
Keywords: prostate cancer; cancer mcrpc; resistant prostate; castration resistant ... See more keywords
Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.155
Abstract: 155Background: Metastatic castration resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. Targeting programmed cell... read more here.
Keywords: castration resistant; resistant prostate; cancer mcrpc; metastatic castration ... See more keywords
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14715
Abstract: Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and… read more here.
Keywords: cancer mcrpc; mcrpc patients; prostate cancer; metastatic castration ... See more keywords